STAAR Surgical Reports 33% Third Quarter Reve...(ing U.S. cataractproduct line to profita...),Health

Date:10/28/2008

ing U.S. cataract product line to profitability, any statements regarding future performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include our limited capital resources and limited access to financing, the effect a prolonged global recession may have on sales of products, especially products such as ICL used in non- reimbursed elective procedures, the challenge of fully integrating STAAR Japan into our business and managing our other foreign subsidiaries, the need to realize product development goals to improve profitability of our U.S. IOL product line, our ability to address FDA concerns over the clinical study for the Toric ICL and to overcome negative publicity resulting from warning letters and other correspondence from the FDA Office of Compliance, the willingness of surgeons and patients to adopt a new product and procedure, the effect of a possible U.S. recession on elective procedures such as refractive surgery, and the potential effect of recent negative publicity about LASIK on the demand for refractive surgery in general in the U.S. STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so.

Use of Non-GAAP information

This news release presents selected items from the Company's Condensed Consolidated Statements of Operations and Condensed Consolidated Statements of Cash Flows as reported in accordance with U.S. generally accepted accounting principles ("GAAP"), and also on a non-GAAP basis after excluding data reported by STAAR Japan.

The Company completed the acquisition of the remaining interests in STAAR Japan on D
'/>"/>

SOURCE STAAR Surgical Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. STAAR Surgical to Present at the Noble Financial Equity Conference
2. STAAR Surgicals Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification
3. STAAR Surgicals LASIK Alternative Expands U.S. Market Gains
4. STAAR Surgical Reports Solid First Quarter Progress
5. STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call
6. STAAR Surgical Plans Major Presence at ASCRS
7. STAAR Surgical Reports Fourth Quarter and Year End Results
8. STAAR Surgicals Visian ICL Procedure Performed Live on NBCs Today show
9. STAAR Surgical Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
10. STAAR Surgical to Present at the Tenth Annual Needham Growth Conference
11. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture